Redx Pharma Plc (LON:REDX)

Redx Pharma Plc (LON:REDX)


Share Price
10.00 p
Change
-2 (-16.67 %)
Market Cap
£12.65 m
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Issue of Warrants and Change to Lease Agreement


RNS Number : 3457R
Redx Pharma plc
28 February 2019
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

REDX PHARMA PLC

("Redx" or "the Company")

 

Issue of Warrants and Change to Lease Agreement

 

Alderley Park, 28 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, as previously noted in its 2018 Annual Report, it has successfully completed an agreement with Alderley Park Limited to significantly reduce its accommodation footprint in the Company's Headquarters at Alderley Park, Cheshire.

 

As part of the agreement, on 27 February 2019, a Warrant to acquire 750,000 ordinary shares of 1p each in the share capital of the Company was issued to Alderley Park Limited as follows:

 

The subscription price payable per warrant share on exercise of the warrant is:

 

Price

No. of Shares

Date of Vesting

13.75p

125,000

27 February 2019

20p

125,000

27 February 2019

27p

125,000

27 February 2020

35p

125,000

27 February 2020

42.5p

125,000

27 February 2021

50p

125,000

27 February 2021

 

The Warrant will not become exercisable until the second anniversary of issue.

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

T: +44 20 7894 7000

Phil Davies

 

 

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKODKFBKDFBB

Redx Pharma Plc Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use